ORIOLA OYJ |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.905 EUR | +1.12% |
|
-14.62% | -16.82% |
| Apr. 30 | Sweden’s Competition Watchdog Prohibits Oriola's Dose Dispensing Unit Sale | MT |
| Apr. 25 | Transcript : Oriola Oyj, Q1 2024 Earnings Call, Apr 25, 2024 |
Strengths
- The earnings growth currently anticipated by analysts for the coming years is particularly strong.
- The company is one of the most undervalued, with an "enterprise value to sales" ratio at 0.1 for the 2024 fiscal year.
- The company appears to be poorly valued given its net asset value.
- Given the positive cash flows generated by its business, the company's valuation level is an asset.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts have consistently raised their revenue expectations for the company, which provides good prospects for the current and next years in terms of revenue growth.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Over the past twelve months, analysts' opinions have been strongly revised upwards.
- The divergence of price targets given by the various analysts who make up the consensus is relatively low, suggesting a consensus method of evaluating the company and its prospects.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- The company has insufficient levels of profitability.
- For the past year, analysts have significantly revised downwards their profit estimates.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
- The overall consensus opinion of analysts has deteriorated sharply over the past four months.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
- The company's earnings releases usually do not meet expectations.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Pharmaceuticals
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -16.82% | 181M | B- | ||
| +14.53% | 69.79B | C+ | ||
| +7.11% | 8.2B | B | ||
| -20.55% | 7.96B | B- | ||
| -5.04% | 7.91B | C | ||
| +2.32% | 4.69B | B- | ||
| +17.12% | 4.32B | B+ | ||
| -1.24% | 3.99B | B- | ||
| -3.78% | 3.81B | B | ||
| +21.42% | 3.62B | C+ |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
Profitability
Finances
Valuation
P/E ratio
EV / Sales
Price to Book
Price to Free Cash Flow
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- OKDBV Stock
- Ratings Oriola Oyj
